Mairéad Ní Chonghaile, RGN, BNS, MSc, speaks on the need for training and support networks in this area of care.
Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Advertisement
Latest News
MDS experts tell of the clinical factors they consider when selecting from the available agent options.
An MDS expert panel discusses findings from the trial's comparison of luspatercept with ESAs in this setting.
Phase II study data demonstrate this benefit in patients with low-risk myeloid malignancies or precursor conditions.
Final data from a phase II trial suggest a promising option for elderly patients with this serious disease.
Dr. Chedid brings an update highlighting the most noteworthy recent findings from MDS clinical trials.
Results from a new analysis further support the initial findings of the global, phase III IMerge trial.
A systematic review found IV administration to have fewer postoperative complications and better quality of life.
Quality of life improvement is among the benefits from this agent in patients with congenital disease.
In PNH not previously treated with C5 inhibitors, crovalimab has shown efficacy noninferior to eculizumab.
An ongoing phase IIA study reports safety and dosing data for patients with transfusion-dependent disease.
Advertisement
MDS Roundtables
Expert Interviews on Hematology
Conference Coverage
Heme Today reports from the EHA 2024 Hybrid Congress the latest findings in hematology research and management.
Highlighting the latest news and experts in pediatric hematology and oncology from the 2024 ASPHO Conference in Seattle.
Our editors are covering data on transplantation and cellular therapies from the 2024 Tandem Meetings of ASTCT® and ...
The editors of Heme Today review major presentations on classical hematology from the 2023 ASH Annual Meeting & ...
